Trial Profile
A Retrospective, Single-Institutional Study Assessing the Safety of TAS-102 with Bevacizumab in Patients with Refractory Metastatic Colorectal Cancer (mCRC) in Real-World Clinical Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 21 Feb 2018 New trial record
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium.